JP7116278B2 - 癌治療のための免疫原性化合物 - Google Patents

癌治療のための免疫原性化合物 Download PDF

Info

Publication number
JP7116278B2
JP7116278B2 JP2019519252A JP2019519252A JP7116278B2 JP 7116278 B2 JP7116278 B2 JP 7116278B2 JP 2019519252 A JP2019519252 A JP 2019519252A JP 2019519252 A JP2019519252 A JP 2019519252A JP 7116278 B2 JP7116278 B2 JP 7116278B2
Authority
JP
Japan
Prior art keywords
peptide
antigenic
cancer
seq
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019519252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534884A (ja
JP2019534884A5 (enExample
Inventor
ローラン・シェーヌ
アルバン・マチュー
マチュー・ピショー
フランチェスコ・ストロッツィ
Original Assignee
エンテローム エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンテローム エスエー filed Critical エンテローム エスエー
Publication of JP2019534884A publication Critical patent/JP2019534884A/ja
Publication of JP2019534884A5 publication Critical patent/JP2019534884A5/ja
Priority to JP2022096260A priority Critical patent/JP7331207B2/ja
Application granted granted Critical
Publication of JP7116278B2 publication Critical patent/JP7116278B2/ja
Priority to JP2023129666A priority patent/JP7648311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2019519252A 2016-10-07 2017-10-09 癌治療のための免疫原性化合物 Active JP7116278B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022096260A JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192948.4 2016-10-07
EP16192948 2016-10-07
PCT/EP2017/075673 WO2018065623A2 (en) 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096260A Division JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物

Publications (3)

Publication Number Publication Date
JP2019534884A JP2019534884A (ja) 2019-12-05
JP2019534884A5 JP2019534884A5 (enExample) 2020-11-19
JP7116278B2 true JP7116278B2 (ja) 2022-08-10

Family

ID=57123864

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019519252A Active JP7116278B2 (ja) 2016-10-07 2017-10-09 癌治療のための免疫原性化合物
JP2022096260A Active JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A Active JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022096260A Active JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A Active JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Country Status (9)

Country Link
US (2) US11478537B2 (enExample)
EP (1) EP3522915A2 (enExample)
JP (3) JP7116278B2 (enExample)
KR (2) KR102622188B1 (enExample)
CN (2) CN110022893B (enExample)
AU (3) AU2017339577B2 (enExample)
CA (1) CA3039322A1 (enExample)
IL (3) IL302345B2 (enExample)
WO (1) WO2018065623A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
LT4021487T (lt) * 2019-11-15 2024-02-12 Enterome S.A. Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui
WO2022015766A1 (en) * 2020-07-13 2022-01-20 Oregon Health & Science University Immunogenic constructs, compositions, and methods for inducing immune response
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
JP2003524016A (ja) 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1496923A4 (en) 2002-03-22 2005-10-19 Penn State Res Found IMMUNOTHERAPY AGAINST CANCER
CN1954217B (zh) * 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008073463A2 (en) 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
MX2010002002A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido foxm1 y agente medicinal que lo contiene.
EP2324057B1 (en) * 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
NO2504364T3 (enExample) 2009-11-24 2018-01-06
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP3855184B1 (en) 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
US20140141044A1 (en) * 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
CA2893359C (en) 2012-12-05 2021-12-28 Strategia Therapeutics, Inc. Protein expression enhancing polypeptides
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
JP7013240B2 (ja) 2015-02-16 2022-01-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９～３７７位エピトープに特異的な完全ヒトＴ細胞受容体
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN108026513A (zh) * 2015-03-31 2018-05-11 新加坡科技研究局 树突状细胞的抗原加载的方法和疫苗
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
JP7232825B2 (ja) 2017-10-09 2023-03-03 エンテローム エスエー 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
LT4021487T (lt) 2019-11-15 2024-02-12 Enterome S.A. Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
JP2003524016A (ja) 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Accession No. C2MB65, version 17, Heavy metal efflux pump, CzcA family，Database Uniprot [online]，2016年09月07日，Retrieved from the Internet, Retrieved on 2021年7月19日，URL:<https://www.uniprot.org/uniprot/C2MB65.txt?version=17>
Accession No. F4KLC2, version 28, Acriflavin resistance protein，Database Uniprot [online]，2016年09月07日，Retrieved from the Internet, [Retrieved on 2021年7月19日]，URL:<https://www.uniprot.org/uniprot/F4KLC2.txt?version=28>
HUARTE E. et al.，Clinical Cancer Research，2002年，Vol.8，p.2336-2344
RODEBERG D. A. et al.，Clin Cancer Res，2005年，11(12)，p.4545-4552
TOURDOT S. et al.，Eur. J. Immunol.，2000年，30，p.3411-3421

Also Published As

Publication number Publication date
JP7648311B2 (ja) 2025-03-18
CN110022893B (zh) 2023-12-29
JP2019534884A (ja) 2019-12-05
IL302345B2 (en) 2024-12-01
EP3522915A2 (en) 2019-08-14
WO2018065623A3 (en) 2018-05-31
IL296165B2 (en) 2023-10-01
WO2018065623A2 (en) 2018-04-12
US12263210B2 (en) 2025-04-01
US20230201322A1 (en) 2023-06-29
IL265751A (en) 2019-05-30
CA3039322A1 (en) 2018-04-12
AU2017339577B2 (en) 2021-12-02
CN110022893A (zh) 2019-07-16
IL265751B2 (en) 2023-02-01
CN117801066A (zh) 2024-04-02
KR20190066028A (ko) 2019-06-12
JP2023156414A (ja) 2023-10-24
IL302345A (en) 2023-06-01
IL296165A (en) 2022-11-01
AU2023222999B2 (en) 2025-07-24
JP2022120137A (ja) 2022-08-17
AU2023222999A1 (en) 2023-09-21
IL296165B1 (en) 2023-06-01
AU2017339577A1 (en) 2019-05-02
AU2022200872B2 (en) 2023-06-29
KR102622188B1 (ko) 2024-01-05
AU2022200872A1 (en) 2022-03-03
KR20240007316A (ko) 2024-01-16
IL302345B1 (en) 2024-08-01
US20200113983A1 (en) 2020-04-16
KR102686875B1 (ko) 2024-07-19
US11478537B2 (en) 2022-10-25
JP7331207B2 (ja) 2023-08-22
IL265751B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
JP7331207B2 (ja) 癌治療のための免疫原性化合物
JP7670445B2 (ja) 癌の予防及び治療のための抗原性ペプチド
US12447201B2 (en) Immunogenic compounds for cancer therapy
JP2023501204A (ja) Ｂ細胞悪性腫瘍の予防及び治療のための抗原性ペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201008

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220615

R150 Certificate of patent or registration of utility model

Ref document number: 7116278

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250